Green and Gray.png
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
21 janv. 2025 09h15 HE | Dogwood Therapeutics, Inc.
ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid,...
Florida Oncology and Hematology Relocates Fort Myers Clinic
Florida Oncology and Hematology Relocates Fort Myers Clinic
21 janv. 2025 08h00 HE | American Oncology Network
Florida Oncology and Hematology Relocates Fort Myers Clinic Local oncology practice moves to a new location.
T.J. Geist, Principal Advocate at Allsup
Allsup Supports Cervical Cancer Awareness Month With SSDI Expertise For Patients
16 janv. 2025 11h45 HE | Allsup
Belleville, Illinois, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Allsup, the nation’s leading provider of Social Security Disability Insurance (SSDI) representation services, is shining a light on Cervical...
Logo_UCBC.jpg
University Cancer & Blood Center physicians recognized among Atlanta’s Top Doctors in Modern Luxury Medicine + Doctors magazine
15 janv. 2025 14h14 HE | University, Cancer and Blood Center
Four physicians from University Cancer & Blood Center are recognized as Top Doctors in Modern Luxury Medicine + Doctors magazine.
AIMLogo.jpg
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
15 janv. 2025 09h05 HE | AIM ImmunoTech Inc.
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces –...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI
13 janv. 2025 08h30 HE | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
Data Update from Phase 2a Arm Evaluating IMM-1-104 with Modified FOLFIRINOX in First Line Pancreatic Cancer as of January 6, 2025
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
13 janv. 2025 08h00 HE | Immuneering Corporation
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
logo.png
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
10 janv. 2025 10h21 HE | BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...
myriad_S_stacked.png
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
07 janv. 2025 08h00 HE | Myriad Genetics, Inc.
The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
Hummingbird.Primary.ColorRGB.png
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
07 janv. 2025 08h00 HE | Hummingbird Bioscience
Hummingbird Bioscience Licenses Novel Antibodies to Immunome